News
-
-
PRESS RELEASE
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
NanoViricides, Inc. announces entering into securities purchase agreement for $3.8 million with institutional investor. Offering to be closed on July 27, 2026. Company offers broad-spectrum antivirals based on nanomedicine technology -
-
PRESS RELEASE
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
NanoViricides, Inc. applies for Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebolavirus in DRC, aiming to combat Ebola outbreak with revolutionary antiviral drug -
-
PRESS RELEASE
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
NanoViricides announces National Ethics Committee approval for Phase II Clinical Trial of NV-387 Oral Gummies as Treatment for Bundibugyo Ebola; focusing on broad-spectrum antiviral treatment for pandemics -
-
PRESS RELEASE
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
NanoViricides, Inc. reports a new research report with 'Outperform' rating and target price of $6.00. Interview with President on antiviral drugs and future plans -
-
PRESS RELEASE
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
NanoViricides, Inc. updates advancement of NV-387 broad-spectrum antiviral drug towards Phase II Clinical Trial for Bundibugyo Ebolavirus treatment in the DRC amid expanding outbreak. An oral gummies formulation has potential against Ebola viruses
